Dyne Medical Group Participates in AUA 2025, Accelerating Entry into the U.S. Market
SNS 기사보내기
페이스북(으)로 기사보내기 트위터(으)로 기사보내기 카카오스토리(으)로 기사보내기 URL복사(으)로 기사보내기 이메일(으)로 기사보내기 다른 공유 찾기 기사Announces official U.S. launch of URUS single-use flexible ureteroscope following FDA approval
Dyne Medical Group (CEO Sunghoon Lee) announced on May 15 that it has showcased the excellence of Korean medical devices for the second consecutive year at the American Urological Association Annual Meeting (AUA).
U.S. physicians testing Dyne Medical Group’s single-use flexible ureteroscope at AUA 2025.
AUA, one of the world’s most prestigious medical congresses, celebrated its 120th anniversary this year with an event held in Las Vegas, USA. Over 30,000 physicians and industry professionals from around the globe attended the event, which concluded successfully.
Dyne Medical Group, the first company in Korea to develop and release a single-use flexible ureteroscope, returned to AUA in 2025 following its debut in 2024.
In 2024, just before receiving FDA approval, the company used the event to introduce its product and establish brand recognition among users, distributors, and industry professionals. This year, the company officially announced the U.S. launch of its FDA-approved URUS single-use flexible ureteroscope, marking a major step forward in entering the U.S. market.
Chulseok Kim, Vice President of Dyne Medical Group and head of U.S. market operations, stated, “Since last year, we have been highlighting URUS’s unique 6 o’clock working channel at various U.S. conferences. This year, we’ve received many inquiries from local distributors interested in our product’s differentiated value and potential.”
Although many companies showcased single-use endoscopes at the AUA exhibition, most were Chinese products with similar specifications. According to attendees, Dyne Medical Group’s URUS stood out as a uniquely differentiated product that captured the attention of users.
One distributor visiting the booth said, “After seeing the Dyne product, I could clearly understand the clinical benefits of its differentiating features. I looked at every other disposable endoscope at the show, but none stood out the way this one did. That’s why I returned to the booth to discuss distribution opportunities.”
This growing interest may be partly attributed to the uncertainty surrounding Chinese products under a potential second Trump administration, which has heightened concerns among U.S. distributors about supply chain disruptions, price fluctuations, and margin instability. Some hospitals are now seeking alternatives to Chinese-made products, increasing attention on URUS—the only Korean-made product in its class.
Prior to AUA, URUS had already been used in real clinical cases at leading hospitals in the U.S., further sparking distributor interest.
Dr. John Lin, a U.S. urologist, visiting Dyne Medical Group’s booth at AUA 2025.
Ahead of the event, successful kidney stone surgeries using the URUS were performed at major hospitals such as UC San Diego Medical Center on the West Coast and AdventHealth, a large hospital network in Florida on the East Coast. These cases helped to validate the product in the eyes of U.S. medical device distributors.
Building on this momentum, Swiss medical device manufacturer EMS—known for its history and credibility—announced a global collaboration with Dyne Medical Group by co-exhibiting at this year’s AUA. This follows their initial partnership agreement formed at last year’s AUA meeting.
Andrew Greenwell, Global Sales Director of EMS, said, “Other endoscope manufacturers approached us solely with low prices. Dyne, however, demonstrated how its product improves usability for physicians and supports better outcomes for patients. It was evident that their research and development efforts are well reflected in the product.”
He continued, “We’ve had several in-depth discussions with Dyne Medical Group, visited their R&D and manufacturing facilities, and concluded that they are a solid partner capable of standing shoulder-to-shoulder with us.”
Overcoming U.S. Market Uncertainty with Product Differentiation — Emerging as a ‘Super Rookie’
Dyne Medical Group plans to build on the many opportunities gained during AUA to establish a strong foothold in the U.S. market.
Vice President Kim noted, “The current economic uncertainty in the U.S. makes it challenging for new medical devices to enter hospitals. However, the response from our local partners has been very encouraging. We plan to proceed step-by-step with institutional sales and expect to see tangible results by the end of this year.”
While most successful Korean medical device companies in global markets have focused on aesthetics and dentistry, Dyne Medical Group is boldly entering the market with a therapeutic device. As a young Korean company, it is drawing attention as a ‘super rookie’ with the potential for even greater success.
Dyne Medical Group Participates in AUA 2025, Accelerating Entry into the U.S. Market
SNS 기사보내기
페이스북(으)로 기사보내기 트위터(으)로 기사보내기 카카오스토리(으)로 기사보내기 URL복사(으)로 기사보내기 이메일(으)로 기사보내기 다른 공유 찾기 기사Announces official U.S. launch of URUS single-use flexible ureteroscope following FDA approval
Dyne Medical Group (CEO Sunghoon Lee) announced on May 15 that it has showcased the excellence of Korean medical devices for the second consecutive year at the American Urological Association Annual Meeting (AUA).
U.S. physicians testing Dyne Medical Group’s single-use flexible ureteroscope at AUA 2025.
AUA, one of the world’s most prestigious medical congresses, celebrated its 120th anniversary this year with an event held in Las Vegas, USA. Over 30,000 physicians and industry professionals from around the globe attended the event, which concluded successfully.
Dyne Medical Group, the first company in Korea to develop and release a single-use flexible ureteroscope, returned to AUA in 2025 following its debut in 2024.
In 2024, just before receiving FDA approval, the company used the event to introduce its product and establish brand recognition among users, distributors, and industry professionals. This year, the company officially announced the U.S. launch of its FDA-approved URUS single-use flexible ureteroscope, marking a major step forward in entering the U.S. market.
Chulseok Kim, Vice President of Dyne Medical Group and head of U.S. market operations, stated, “Since last year, we have been highlighting URUS’s unique 6 o’clock working channel at various U.S. conferences. This year, we’ve received many inquiries from local distributors interested in our product’s differentiated value and potential.”
Although many companies showcased single-use endoscopes at the AUA exhibition, most were Chinese products with similar specifications. According to attendees, Dyne Medical Group’s URUS stood out as a uniquely differentiated product that captured the attention of users.
One distributor visiting the booth said, “After seeing the Dyne product, I could clearly understand the clinical benefits of its differentiating features. I looked at every other disposable endoscope at the show, but none stood out the way this one did. That’s why I returned to the booth to discuss distribution opportunities.”
This growing interest may be partly attributed to the uncertainty surrounding Chinese products under a potential second Trump administration, which has heightened concerns among U.S. distributors about supply chain disruptions, price fluctuations, and margin instability. Some hospitals are now seeking alternatives to Chinese-made products, increasing attention on URUS—the only Korean-made product in its class.
Prior to AUA, URUS had already been used in real clinical cases at leading hospitals in the U.S., further sparking distributor interest.
Dr. John Lin, a U.S. urologist, visiting Dyne Medical Group’s booth at AUA 2025.
Ahead of the event, successful kidney stone surgeries using the URUS were performed at major hospitals such as UC San Diego Medical Center on the West Coast and AdventHealth, a large hospital network in Florida on the East Coast. These cases helped to validate the product in the eyes of U.S. medical device distributors.
Building on this momentum, Swiss medical device manufacturer EMS—known for its history and credibility—announced a global collaboration with Dyne Medical Group by co-exhibiting at this year’s AUA. This follows their initial partnership agreement formed at last year’s AUA meeting.
Andrew Greenwell, Global Sales Director of EMS, said, “Other endoscope manufacturers approached us solely with low prices. Dyne, however, demonstrated how its product improves usability for physicians and supports better outcomes for patients. It was evident that their research and development efforts are well reflected in the product.”
He continued, “We’ve had several in-depth discussions with Dyne Medical Group, visited their R&D and manufacturing facilities, and concluded that they are a solid partner capable of standing shoulder-to-shoulder with us.”
Overcoming U.S. Market Uncertainty with Product Differentiation — Emerging as a ‘Super Rookie’
Dyne Medical Group plans to build on the many opportunities gained during AUA to establish a strong foothold in the U.S. market.
Vice President Kim noted, “The current economic uncertainty in the U.S. makes it challenging for new medical devices to enter hospitals. However, the response from our local partners has been very encouraging. We plan to proceed step-by-step with institutional sales and expect to see tangible results by the end of this year.”
While most successful Korean medical device companies in global markets have focused on aesthetics and dentistry, Dyne Medical Group is boldly entering the market with a therapeutic device. As a young Korean company, it is drawing attention as a ‘super rookie’ with the potential for even greater success.